Tabla de Contenidos: “…-- Relationship Investing -- Understanding Market-Neutral Approaches -- Developments in the Hedge Fund Industry -- Hedge Fund Industry Assets -- Hedge Fund Investors -- Hedge Fund Strategies -- Making an Investment in Market-Neutral Strategies -- Linear Analysis of Returns -- Reducing Exposure to Risk -- Market-Neutral and Hedged Strategies -- Convertible Arbitrage -- Fixed-Income Arbitrage -- Mortgage-Backed Securities Arbitrage -- Merger Arbitrage -- Equity Hedge -- Equity Market-Neutral and Statistical Arbitrage -- Relative Value Arbitrage -- Achieving Superior Risk-Adjusted Returns -- Assessing the Risks -- Transparency -- Focusing on the Underlying Strategies -- Convertible Arbitrage -- Convertible Bond Valuation -- Statistical Advantage -- Convertible Valuation Components -- Convertible Arbitrage Approaches -- Quantitative Screens -- Kinds of Hedges -- Setting Up a Market-Neutral Hedge -- Setting up a Bullish Hedge --…”

Tabla de Contenidos: “…Blonigen and Robert F. Krueger -- Exposure to violence, mental health, and violent behavior / Daniel J. …”

Tabla de Contenidos: “…Corning and Isabella M. Viducich -- Trauma exposure in posttraumatic stress and acute stress disorders / Annette M. …”

Tabla de Contenidos: “…11 The Realization of Nanotechnology -- 11.1 Nanospeci cation -- 11.2 Standardization of Nanotechnology -- 11.3 Nanometrology -- 11.4 The Nanometrology Instrument Industry -- References -- Further Reading -- 12 The Business Environment -- 12.1 The Universality of Nanotechnology -- 12.2 The Radical Nature of Nanotechnology -- 12.3 Intellectual Needs -- 12.4 Company-University Collaboration -- 12.5 Clusters -- 12.6 Assessing Demand for Nanotechnology -- 12.6.1 Modeling -- 12.6.2 Judging Innovation Value -- 12.6.3 Anticipating Bene t -- 12.7 Technical and Commercial Readiness (Availability) Levels -- 12.8 Predicting Development Timescales -- 12.9 Patents -- 12.10 Generic Business Models -- 12.11 Why Nanotechnology Companies Often Fail -- References -- Further Reading -- 13 The Fiscal Environment of Nanotechnology -- 13.1 Sources of Funds -- 13.2 Private Investment -- 13.3 Government Funding -- 13.4 Endogenous Funding -- 13.5 Geographical Differences Between Nanotechnology Funding -- References -- Further Reading -- 14 The Safety of Nanofacture and Nanomaterials -- 14.1 Public Perception of the Safety of Nanoproducts -- 14.2 Evaluating Risk -- 14.3 Evaluating the Toxicity of Nanomaterials -- 14.4 Characteristic Features of Nano-Objects -- 14.5 Exposure -- 14.5.1 Occupational Exposure (During Nanofacture) -- 14.5.2 Public Exposure (During Use) -- 14.6 Penetrability and clearance -- 14.7 Hazard -- 14.8 Variability of Individual Response -- 14.9 Risks to Vital Ecosystems -- 14.10 "Natural" Exposure to Nanoparticles -- 14.11 A Rational Basis for Safety Measures -- 14.12 Bow Tie Diagrams -- References -- Further Reading -- 15 Regulation -- References -- Further Reading -- 16 Some Successful and Unsuccessful Nanotechnology Companies -- 16.1 NanoMagnetics -- 16.2 MesoPhotonics -- 16.3 Enact Pharma -- 16.4 Oxonica -- 16.5 NanoCo -- 16.6 Hyperion -- 16.7 CDT…”

Tabla de Contenidos: “…. -- Statement of Problems -- Question Presented -- Conclusion -- Discussion of Authority -- The Delaney Committee Report -- The Pesticide Residues Amendments -- The Food Additives Amendment -- 1956 Hearings -- 1958 Hearings -- Addition of the Delaney Clause -- NOTES -- B Analytical Methodology for Estimating Oncogenic Risks of Human Exposure to Agricultural Chemicals In Food Crops -- Datamanagement System -- Data Base Construction -- Tape-to-Mainframe Transfer and Data Transformations -- Mainframe-to-Microcomputer Transfer…”

Tabla de Contenidos: “…Foreword -- Abbreviations and acronyms -- ACKNOWLEDGEMENTS -- Executive summary -- Summary recommendations -- INTRODUCTION -- 1.1 Background and rationale -- 1.2 Objectives -- 1.3 Target audience -- 1.4 Guiding principles -- 1.5 Methods for developing the guidelines -- 1.6 Organization of the guidelines -- HIV TESTING AND DIAGNOSIS -- 2.1 Introduction -- 2.2 HIV testing for a changing epidemic -- 2.3 Mobilizing demand and pre-test services -- 2.4 HIV testing service delivery approaches -- 2.5 Post-test services and linkage to prevention, treatment and other services -- 2.6 Strategies to make HIV testing services accessible -- 2.7 Maintaining the accuracy and reliability of HIV diagnosis -- 2.8 HIV diagnosis among infants and children -- HIV prevention -- 3.1 Combination HIV prevention -- 3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV -- 3.3 Post-exposure prophylaxis -- 3.4 Infant prophylaxis -- ANTIRETROVIRAL THERAPY -- 4.1 Introduction -- 4.2 Preparing people living with HIV for ART -- 4.3 What to expect in the first months of ART -- 4.4 When to start ART -- 4.5 Timing of ART -- 4.6 What to start -- 4.7 Monitoring the response to ART -- 4.8 Monitoring ARV toxicity -- 4.9 ARV drug resistance -- 4.10 Key ARV drug interactions -- Managing advancedHIV disease -- 5.1 Introduction -- 5.2 Causes of morbidity and mortality among adults with advanced HIV disease -- 5.3 Providing a package of care -- 5.4 Overview of clinical management of cryptococcal disease -- 5.5 Overview of clinical management of histoplasmosis -- 5.6 Advanced HIV disease among children and adolescents -- 5.7 Supporting decision-making for providing a packageof care -- 5.8 Programme considerations -- GENERAL CARE AND MANAGING COMMON COINFECTIONS AND COMORBIDITIES -- 6.1 Introduction -- 6.2 General care for people living with HIV -- 6.3 Co-trimoxazole prophylaxis…”